Literature DB >> 1295051

Stereotactic resection and its limitations in glial neoplasms.

P J Kelly1.   

Abstract

With imaging-based volumetric stereotactic techniques, it is possible to selectively and accurately remove any CT- or MRI-defined part or all of any intra-axial neoplasm. However, glial neoplasms are composed of two elements: tumor tissue and isolated tumor cells which infiltrate brain parenchyma. In high-grade gliomas and pilocytic astrocytomas, the tumor tissue component is most accurately defined by the volume of contrast enhancement. Tumor tissue in low-grade nonpilocytic gliomas is indistinguishable on imaging from infiltrated parenchyma. Stereotactic biopsy is presently the only method by which CT hypodense tumor tissue can be differentiated from infiltrated parenchyma, which is also hypodense. In eloquent brain areas, stereotactic resection is appropriate for the tumor tissue component only in patients harboring glial tumors.

Entities:  

Mesh:

Year:  1992        PMID: 1295051     DOI: 10.1159/000098922

Source DB:  PubMed          Journal:  Stereotact Funct Neurosurg        ISSN: 1011-6125            Impact factor:   1.875


  7 in total

Review 1.  Toward effective immunotherapy for the treatment of malignant brain tumors.

Authors:  Duane A Mitchell; John H Sampson
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

Review 2.  The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.

Authors:  Amy B Heimberger; John H Sampson
Journal:  Expert Opin Biol Ther       Date:  2009-08       Impact factor: 4.388

3.  Symptomatic intracranial hemorrhages and frame-based stereotactic brain biopsy.

Authors:  Monica Lara-Almunia; Javier Hernandez-Vicente
Journal:  Surg Neurol Int       Date:  2020-08-01

4.  CT-guided computer-assisted stereotactic resection of brain tumours.

Authors:  A G Melikian; M I Kazarnovskaya; A V Stock; A V Golanov; S M Ignatov; S A Lobanov
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

Review 5.  The impact of technical adjuncts in the surgical management of cerebral hemispheric low-grade gliomas of childhood.

Authors:  M S Berger
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

Review 6.  Antibody-based immunotherapy for malignant glioma.

Authors:  Patrick C Gedeon; Katherine A Riccione; Peter E Fecci; John H Sampson
Journal:  Semin Oncol       Date:  2014-06-12       Impact factor: 4.929

Review 7.  Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

Authors:  John H Sampson; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Darell D Bigner
Journal:  Semin Immunol       Date:  2008-06-09       Impact factor: 11.130

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.